Description
Potassium canrenoate is a mineralocorticoid/aldosterone antagonist that exhibits cardioprotective, nephroprotective, antihypertensive, and anti-fibrotic activities. In animal models of cardiac ischemia/reperfusion, potassium canrenoate increases phosphorylation of ERK1/2 and Akt, decreasing infarct size in an adenosine receptor-dependent manner. Potassium canrenoate also improves high salt diet-induced renal dysfunction, reversing the effects of hypofiltration. Additionally, potassium canrenoate displays negative inotropic activity at high doses, decreasing heart rate, blood pressure, and ventricular contraction; it also prolongs ventricular repolarization and the refractory period.